For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
2
views
20
references
 Top references
cited by
20
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
1 collections
    0
    shares
      415
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Omicron: a drug developer’s perspective

      article-commentary
      Author(s): a , b
      Publication date (Electronic, pub):
      Publication date (Electronic, collection):
      Journal: Emerging Microbes & Infections
      Publisher: Taylor & Francis
      Keywords: COVID19, SARS-CoV-2, Omicron variants, COVID19vaccines, COVID19drugs

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          We performed an annotation of 35 mutations in the spike protein of the SARS-CoV-2 Omicron variant. Our analysis of the mutations indicates that Omicron has gained prominent immune evasion and potential for enhanced transmissibility. Previous modeling study has revealed that continued evolution in both immune evasion and enhanced transmissibility by SARS-CoV-2 would compromise vaccines as tools for the pandemic control. To combat the future variants of SARS-CoV-2, the world needs novel antiviral drugs that are effective at curb viral spreading without introducing additional selective pressure towards resistant variants.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found

          Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding

          Tyler N. Starr, Allison J. Greaney, Sarah K Hilton … (2021)
          Summary The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein mediates viral attachment to ACE2 receptor, and is a major determinant of host range and a dominant target of neutralizing antibodies. Here we experimentally measure how all amino-acid mutations to the RBD affect expression of folded protein and its affinity for ACE2. Most mutations are deleterious for RBD expression and ACE2 binding, and we identify constrained regions on the RBD’s surface that may be desirable targets for vaccines and antibody-based therapeutics. But a substantial number of mutations are well tolerated or even enhance ACE2 binding, including at ACE2 interface residues that vary across SARS-related coronaviruses. However, we find no evidence that these ACE2-affinity enhancing mutations have been selected in current SARS-CoV-2 pandemic isolates. We present an interactive visualization and open analysis pipeline to facilitate use of our dataset for vaccine design and functional annotation of mutations observed during viral surveillance.
          Article 0 comments Cited 1011 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity

            Erik Volz, Verity Hill, John McCrone … (2020)
            Global dispersal and increasing frequency of the SARS-CoV-2 Spike protein variant D614G are suggestive of a selective advantage but may also be due to a random founder effect. We investigate the hypothesis for positive selection of Spike D614G in the United Kingdom using more than 25,000 whole genome SARS-CoV-2 sequences. Despite the availability of a large data set, well represented by both Spike 614 variants, not all approaches showed a conclusive signal of positive selection. Population genetic analysis indicates that 614G increases in frequency relative to 614D in a manner consistent with a selective advantage. We do not find any indication that patients infected with the Spike 614G variant have higher COVID-19 mortality or clinical severity, but 614G is associated with higher viral load and younger age of patients. Significant differences in growth and size of 614G phylogenetic clusters indicate a need for continued study of this variant.
            Article 0 comments Cited 463 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

              Matthew McCallum, Anna De Marco, Florian A. Lempp … (2021)
              The SARS-CoV-2 spike (S) glycoprotein contains an immunodominant receptor-binding domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient plasma. Little is known about neutralizing Abs binding to epitopes outside the RBD and their contribution to protection. Here, we describe 41 human monoclonal Abs (mAbs) derived from memory B cells, which recognize the SARS-CoV-2 S N-terminal domain (NTD) and show that a subset of them neutralize SARS-CoV-2 ultrapotently. We define an antigenic map of the SARS-CoV-2 NTD and identify a supersite (designated site i) recognized by all known NTD-specific neutralizing mAbs. These mAbs inhibit cell-to-cell fusion, activate effector functions, and protect Syrian hamsters from SARS-CoV-2 challenge, albeit selecting escape mutants in some animals. Indeed, several SARS-CoV-2 variants, including the B.1.1.7, B.1.351 and P1 lineages, harbor frequent mutations within the NTD supersite suggesting ongoing selective pressure and the importance of NTD-specific neutralizing mAbs for protective immunity and vaccine design.
              Article 0 comments Cited 454 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Emerg Microbes Infect
                Journal ID (iso-abbrev): Emerg Microbes Infect
                Title: Emerging Microbes & Infections
                Publisher: Taylor & Francis
                ISSN (Electronic): 2222-1751
                Publication date (Electronic, pub): 4 January 2022
                Publication date (Electronic, collection): 2022
                Publication date PMC-release: 4 January 2022
                Volume: 11
                Issue: 1
                Pages: 208-211
                Affiliations
                [a ]Abimmune Biopharma, Inc. , San Diego, CA, USA
                [b ]Department of Biochemistry and Molecular Biology, Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch , Galveston, TX, USA
                Author notes
                [CONTACT ] Fang “Flora” Fang flora@ 123456abimmunebio.com Abimmune Biopharma, Inc. , San Diego, CA, USA
                Article
                Publisher ID: 2023330
                DOI: 10.1080/22221751.2021.2023330
                PMC ID: 8741250
                PubMed ID: 34951568
                SO-VID: 7294200e-3947-4ceb-bb8d-ca029dcecde1
                Copyright © © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
                License:

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                Page count
                Figures: 0, Tables: 1, Equations: 0, References: 20, Pages: 4
                Categories
                Subject: Coronaviruses
                Subject: Article Commentary

                Keywords: covid19,sars-cov-2,omicron variants,covid19vaccines,covid19drugs
                Data availability:
                Keywords: covid19, sars-cov-2, omicron variants, covid19vaccines, covid19drugs

                Comments

                Comment on this article

                scite_

                Similar content415

                See all similar

                Cited by20

                See all cited by

                Most referenced authors590

                See all reference authors